Recursion Pharmaceuticals, Inc.
NASDAQ:RXRXBiotechnology
+$0.04 today
- Market cap
- $1.76B
- Beta
- 1.00
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$1.06
Volume 41.13M
Average 15.60M
RXRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Recursion Pharmaceuticals, Inc.NASDAQ: RXRX
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $89.61M fell 30.3% year over year, behind the -11.4% change in trailing-twelve-month research & development. Sequentially, it rose 2.0% from the prior quarter. Over 3 fiscal years it compounded at +39.8% a year.
Context
- Research & development amounted to 569.4% of revenue in FY2025, up 35.1 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -30.3% toward the trailing-twelve-month pace of -11.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 425.27M USD
- Year-over-year change
- +35.3%
- 4-year CAGR
- +33.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 425.27M | +35.3% |
| FY2024 | 2024-12-31 | 314.42M | +30.3% |
| FY2023 | 2023-12-31 | 241.23M | +54.9% |
| FY2022 | 2022-12-31 | 155.7M | +15.1% |
| FY2021 | 2021-12-31 | 135.27M | — |
Research & Development vs competitors
How RXRX compares with its peers on the latest reported figures
- RXRX's LTM Jun 2026 research & development of $381.91M is the 2nd highest of the 4 companies compared; the peer median is $270.72M.
- Its year-over-year change of -11.4% is the lowest of 4, against a peer median of -3.9%.
- Research & development amounts to 696.2% of revenue for RXRX, versus a peer median of 2615.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $400.72M | -3.9% | +5.3% | 11118.8% | |
| LTM Jun 2026 | $381.91M | -11.4% | +39.8% | 696.2% | |
| LTM Jun 2026 | $270.72M | -4.1% | +2.0% | 2615.7% | |
| LTM Mar 2026 | $114.57M | +28.4% | +7.1% | 572.9% | |
| Peer median (excluding RXRX) | $270.72M | -3.9% | +5.3% | 2615.7% | |
Competitors are the stored peer set for RXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10M | 39.68M | 43.88M | 58.84M | 74.68M |
| Cost of Revenue | 0 | 48.28M | 42.59M | 45.24M | 120.95M |
| Gross Profit | 10M | (8.59M) | 1.29M | 13.6M | (46.27M) |
| Gross Margin | 100.0% | -21.7% | 2.9% | 23.1% | -62.0% |
| Research & Development | 135.27M | 155.7M | 241.23M | 314.42M | 425.27M |
| Selling, General & Admin | 57.68M | 81.6M | 110.82M | 178.18M | 176.59M |
| Operating Expenses | 192.78M | 237.13M | 351.35M | 492.61M | 601.86M |
| Depreciation & Amortization | 8.41M | 11.76M | 24.4M | 36.49M | 83.7M |
| EBITDA | (175.12M) | (227.67M) | (307.63M) | (426.72M) | (559.38M) |
| EBITDA Margin | -1751.2% | -573.7% | -701.1% | -725.2% | -749.0% |
| Operating Income | (182.78M) | (245.73M) | (350.06M) | (479M) | (648.13M) |
| Operating Margin | -1827.8% | -619.3% | -797.8% | -814.1% | -867.9% |
| Interest Income | 73K | 6.25M | 19.12M | 15.76M | 22.79M |
| Interest Expense | 2.95M | 55K | 97K | 1.57M | 1.81M |
| Other Income / Expenses | (3.7M) | 6.25M | 17.93M | 14.22M | 3.24M |
| Income Before Tax | (186.48M) | (239.48M) | (332.13M) | (464.79M) | (644.9M) |
| Pre-Tax Margin | -1864.8% | -603.5% | -757.0% | -789.9% | -863.5% |
| Income Tax Expense | 0 | 0 | (4.06M) | (1.13M) | (136K) |
| Net Income | (186.48M) | (239.48M) | (328.07M) | (463.66M) | (644.76M) |
| Net Margin | -1864.8% | -603.5% | -747.7% | -788.0% | -863.4% |
| EPS (Basic) | (1.05) | (1.36) | (1.58) | (1.69) | (1.44) |
| EPS (Diluted) | (1.05) | (1.36) | (1.58) | (1.69) | (1.44) |
| Weighted Avg Shares | 170.27M | 175.54M | 207.85M | 274.21M | 447.45M |
| Weighted Avg Shares (Diluted) | 170.27M | 175.54M | 207.85M | 274.21M | 447.45M |
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
Intrinsic Alpha fair value
Locked
Current Price
$2.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.